BioVie 6M share Secondary priced at $2.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Offering Details: The deal was priced below the last closing price of $2.91, with ThinkEquity serving as the sole book running manager for the offering.
Market Context: This pricing indicates a potential strategy to attract investors despite being lower than recent market performance.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BIVI with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BIVI
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New to The Street Broadcasts Show #716 Featuring SDST and Others
- Broadcast Timing: New to The Street will air Show #716 tonight at 6:30 PM Eastern Time on Bloomberg Television, enhancing its influence in the business media landscape by showcasing various public companies.
- Company Highlights: The episode will spotlight Stardust Power Inc. (NASDAQ:SDST), BioVie Inc. (NASDAQ:BIVI), and Roadzen Inc. (NASDAQ:RDZN), showcasing innovations in critical minerals, biotechnology, and AI-driven mobility and insurance solutions, aimed at attracting investor interest.
- Celebrity Features: The show will also include special segments with Kelsey Grammer discussing his new book KAREN and Andrew Shaw introducing his nonprofit 250DAYS.ORG, emphasizing the importance of mental health awareness and recovery, thereby enhancing the program's social impact.
- International Expansion Plans: New to The Street plans to launch its international version in the MENA region on January 24, 2026, further expanding its global reach, while also preparing to launch the Spanish-language platform Nuevo En La Calle, showcasing its diversified media strategy.
Continue Reading
BioVie Inc. Investigated for Potential Breach of Fiduciary Duties by Executives
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether executives of BioVie Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of BioVie may seek corporate governance reforms, fund recovery, or court-approved financial incentives, aimed at enhancing company transparency and accountability.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value and increasing the effectiveness of corporate management.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
Continue Reading